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GENETIC VARIENTS LEADING TO ATRIAL FIBRILLATION 
 
ELIZABETH ABRAHAM 
ABSTRACT 
Background   
Atrial Fibrillation (AF) is the most common cardiac arrhythmia, affecting over 3 million 
Americans. Many people who suffer from AF have pre-disposing factors such as 
hypertension, ischemia, and structural heart disease, but recent research has also 
demonstrated the importance of genetic factors that can contribute to AF. In the present 
study, we sought to determine the causative mutation in a family with AF, atrial septal, 
and ventricular septal defects.  
Methods 
We evaluated a pedigree with 16 family members, one of whom had an ASD, one a VSD, 
and three had AF. Exome sequencing was performed on three of the five affected family 
members followed by confirmation with Sanger sequencing in all family members. A 
separate cohort from the MGH AF Study with early-onset AF (age at onset 47.1 ± 10.9 
years, 79.3% male) was also screened for mutations using a combination of Sanger 
sequencing and high resolution melting. Variants were then functionally characterized 
using reporter assays in a mammalian cell line using wild-type and mutant constructs 
driving NPPA, αMHC and NPPB promoter reporters.	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Results	  
Exome sequencing of the three affected individuals in the family identified a highly 
conserved mutation, R585L, in the transcription factor gene, GATA6.  We also identified 
three additional GATA6 variants (P91S, A177T, and A543G) in the cases with early-onset 
AF from the MGH AF Study.  We found that three of the four variants had a marked 
upregulation of luciferase activity (R585L; 4.1 fold, p<0.0001; P91S; 2.5 fold, p=0.0002; 
A177T; 1.7 fold, p=0.03). Additionally, when co-overexpressed with GATA4 and 
MEF2C, all GATA6 variants exhibited upregulation of the αMHC and NPPA activity 
compared to control.  
Conclusion 
Overall, we found gain-of-function mutations in GATA6 in both a family with early-onset 
AF and atrioventricular septal defects as well as in patients with sporadic, early-onset AF. 
This evidence suggests that specific gain of function mutations in GATA6 contribute to 
the development of AF.  
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INTRODUCTION 
Atrial Fibrillation (AF) is the most common heart arrhythmia affecting about 5.2 
million in the United States and nearly 30 million people worldwide (Chugh et al., 2014). 
The number of cases in the U.S. alone is expected to double by 2030 (Colilla et al., 
2013), making research into the etiology and causes of AF a necessity. AF affects the 
electrical functioning of the atria or upper chambers of the heart and can be described as 
an irregular, rapid heartbeat. Although AF is often considered a minor issue, it commonly 
causes blood clots, stroke, myocardial infarction, dementia and heart failure (Mozaffarian 
et al., 2016). In the Framingham Heart Study, a nearly five-fold increased incidence of 
stroke was found in patients with AF in the absence of coronary heart disease and heart 
failure. When concomitant with heart failure and coronary heart disease AF further 
increases ones risk of stroke as compared to individuals with coronary heart failure and 
heart failure alone (Wolf, Abbott, & Kannel, 1991). Additionally, individuals with AF  
have about twice the risk of death as compared to the general population (Benjamin et al., 
1998). 
I. Pathophysiology of AF 
Physiologically, AF reduces cardiac output thus decreasing blood flow to the 
brain and other organs.  There is no known cure for this disease and current treatment 
options are limited, making research into its mechanisms and pathophysiology paramount 
(Prystowsky, Padanilam B.J., & Waldo A.L., n.d.). AF typically originates from a rapidly 
firing ectopic loci within the proximal pulmonary veins and an abnormal atrial tissue that 
maintains this arrhythmia by allowing it to propagate via re-entrant loops. Chronic AF is 
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also capable of changing overall atrial electrophysiology by causing refractory period 
shortening, which further perpetuates the arrhythmia in a vicious cycle. The majority of 
people who suffer from AF have pre-disposing factors that increase their risk of 
developing the disease such as, hypertension, ischemia, and/or structural heart disease 
(Markides & Schilling, 2003). Other risk factors include: age, sex, valvular heart disease, 
cardiomyopathy, diabetes mellitus, obesity, sleep apnea, chronic kidney disease, thyroid 
dysfunction, smoking, and alcohol consumption (Andrade, Khairy, Dobrev, & Nattel, 
2014).   
Atrial and ventricular septal defects are common congenital structural heart 
defects that can often lead to AF, even after surgical treatment. Both are holes in the heart 
wall (separating the two atria and ventricles respectively) that fail to close properly 
during development. The severity of these defects can vary from almost undetectable to 
life-threatening. Congenital heart disease is the most common birth defect affecting 1-2% 
of newborns. The incidence of arrhythmias increases as the individual with a heart defect 
ages (Khairy & Balaji, 2009).  
II. Early Genetic Studies  
AF is often secondary to other conditions however, up to 30% of patients have 
lone, or idiopathic AF (Parvez & Darbar, 2011). Recently, researchers have discovered a 
number of genetic factors that are known to contribute to AF, especially in cases in which 
first degree relatives are known to have the disease (Steffensen et al., 2015).  
The first study of related families with early onset AF to establish that there is a 
genetic basis for the disease was in 1997 (Brugada et al.). This study screened a 26-
	  3 
member family, 10 of which had AF, and performed linkage analysis and found that their 
disease was linked to a single locus. They also found similar results in two separate 
families. Soon after, Chen et al. (2003) discovered the first genetic mutation causing AF 
in the potassium voltage gated subfamily Q member 1 gene (KCNQ1). The study 
examined the gene sequences of a family with hereditary persistent AF and found a 
mutation in a KCNQ1 gene that was not present in normal individuals. This research has 
spurred much investigation into the genetic basis for AF.  
III. Heritability of AF 
Familial studies give us insight to rare variants with a very high penetrance (such 
as KCNQ1). Meaning, the chances of developing AF increase dramatically if you have 
one of these variants. Based on data from the Framingham Heart Study a person’s chance 
of developing AF increases about 40% with one immediate family member having the 
disease (Figure 1) (Lubitz SA, Yin X, Fontes JD, & et al, 2010). Whereas if one has a 
variant within a locus found in one of the genome wide association studies (GWAS, 
described below), that person’s chance of developing AF is not quite as high 
(approximately a 10% increased risk) (Figure 2). This is because GWAS variants are 
more common and are not typically inherited.  
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Figure 1. AF in first degree relatives associated with an increased risk of AF, 
(Lubitz et al 2010).  
Heritability may also play a role in nonfamililal atrial fibrillation. Christophersen 
et al. studied Danish monozygotic (identical) and dizygotic (fraternal) twins and 
examined their risk for developing AF if their co-twin has the disease. They found that 
concordance rates for identical twins were two times greater than for fraternal twins 
(2009). Because identical twins have the same genome this study suggests that the 
variation in the concordance rates between identical and fraternal twins is entirely 
dependent on their genes. 
A similar study sought to determine heritability of AF in Icelanders. Icelanders 
are a relatively homogeneous population in terms of both genetic and environmental 
factors. This study found that first degree relatives of AF patients were more than four 
times more likely to develop AF and also that second degree relatives of AF patients had 
a higher risk of developing the disease than the general population. This is significant 
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because it ascribes more weight to the genetic basis of AF and rather than the home 
environment (Arnar et al., 2006).  
The MGH lone AF registry has also been examined along with their families 
which found that over one third of these patients had evidence of familial disease. They 
also validated that members of patient’s families with lone AF have a much higher 
prevalence of AF as compared to the general population. The family members of 
probands with lone AF have a significantly increased risk of AF compared to that of the 
general population. The overall sibling recurrence risk ratio was 57 (Ellinor, Yoerger, 
Ruskin, & MacRae, 2005). This large relative risk to siblings is strongly suggestive of a 
Mendelian mode of inheritance. 
IV. GWAS Studies 
Due to technological advances in genotyping, many studies have performed 
GWAS using much larger cohorts of patients to identify different susceptibility loci. 
These large cohorts compare participants suffering from AF against those who do not 
suffer from the disease to find genetic factors that differ between them. The first GWAS 
was performed in an Icelandic population and lead to the discovery of a susceptibility 
locus near the Paired-like homeodomain 2 gene (PITX2) that was later also replicated in 
European and Asian populations (Gudbjartsson et al., 2007). In 2009, another locus was 
identified by two separate groups within the Zinc finger homeobox 3 gene (ZFHX3-
which also encodes a transcription factor) in Europeans and Han Chinese populations 
(Gudbjartsson et al., 2009) (Benjamin et al., 2009). Another one of the earliest GWAS 
was conducted using 1,335 cases of lone AF and 12,844 control patients of European 
	  6 
decent. This GWAS study uncovered another common AF risk locus, KCNN3, a calcium 
activated potassium channel (Ellinor et al., 2010). 
In 2012 a GWAS meta-analysis compared 6,000 individuals with AF to over 
50,000 without and identified 6 additional variants. Recently, many new loci were 
explored by Sinner et al. in a GWAS cross ethnic study, which took this idea further by 
comparing completely different cultures. Sinner et al. identified 5 novel loci for AF in 
two different populations of Europeans and Japanese patients with AF (2014). Very 
recently, a much larger consortium of 19,000 AF patients was utilized to identify 7 
additional loci with a much greater power (Ellinor, unpublished).  
In sum, there are currently 23 AF susceptibility loci known that have been 
identified using GWAS. Of these loci, five are known transcription factors six are ion 
channels and related proteins, three are known myocyte proteins, and the remaining nine 
have an unclear relation to AF. These studies show that there are many genes that can 
contribute to AF. Although their exact mechanisms of action and interplay remain 
unclear, these studies provide direction for future investigation of the molecular pathways 
indicated.  
Of note, in current AF GWAS studies the most strongly associated locus is near 
PITX2. PITX2 is a transcription factor for which a more defined mechanism exists (A 
Palatinus & Das, 2015). PITX2 deletion studies have shown an increase in gene 
expression in genes specific to the sinoatrial (SA) node. Additionally, PITX2 has been 
shown to down-regulate the expression of Nppa (nautriuretuc peptide A-which regulates 
intravascular volume) and KCNQ1 (encodes a potassium channel). Variants in Nppa and 
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KCNQ1 have both been linked to cases of familial AF and have caused atrial action 
potential (AP) shortening and changes in calcium currents (Zhou, Liao, & Tu, 2015). 
V. Missing Heritability of AF 
GWAS studies help us identify common variants within populations that have AF 
while familial studies add another important piece to this puzzle; namely, rare variants 
with high penetrance. Still, there is a substantial amount of grey area in-between these 
two extremes and a gap between the current number of variants found to date and the 
population attributed risk (Magnani et al., 2011). Overall, the risks associated with 
common variants found to date statistically only explain 10% of the heritability of AF 
(Parvez & Darbar, 2011). 
This missing heritability could be due to common variants that have not been 
found by GWAS, epigenetics, rare variants with strong effects, large or small copy 
number variants, and mosaicism (when the genomic content is not uniform across all 
cells, mainly due to errors in cell division) which is difficult to assess with current 
techniques (Tucker, Clauss, & Ellinor, 2016). These errors include single nucleotide 
substitutions, copy number alterations, rearrangement, and chromosome gains and losses. 
Mosaicism is often recognized as being responsible for germline disorders (for example, 
nondisjunction in trisomy 21) but it can also occur within somatic cells in which case 
these errors can accumulate over time (De, 2011). 
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Figure 2. Frequency of known AF genetic variants versus effect size, (Magnani et al., 
2011). 
While mosaicism and lower frequency variants with intermediate effect sizes are 
harder to detect, it is hoped that much of this missing genetic component will be 
discovered as further advances in sequencing technology (such as whole-genome 
sequencing) become more readily available. 
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VI. Treatments of AF: Present and Future 
 In clinic AF is typically initially treated with beta-blockers and blood 
thinners. Beta-blockers are used to slow the overall heart rate to prevent the rapid firing 
from the atria from propagating to the ventricles while blood thinners are used to prevent 
stroke. If a patients AF progresses to severe and symptomatic antiarrhythmic drug (AAD) 
therapy may be attempted. The most common antiarrhythmic used is Amiodarone, which 
prolongs the cardiac action potential mainly by blocking sodium and potassium channels. 
A major downside of these antiarrhythmic drugs is that they have high toxicities and can 
actually be proarrythmic at certain doses. Also, over half of patients treated with 
antiarrhythmic drugs experience a reoccurrence of AF within one year (Hohnloser, Kuck, 
& Lilienthal, 2000).  If antiarrhythmic drug therapy is unsuccessful catheter based 
ablation can be performed. The procedure burns atrial tissue (usually around the 
pulmonary veins) to electrically isolate that arrhythmogenic area to stop it from 
spreading. This is can be a very effective procedure initially, however, over time AF 
likely to reoccur especially in older patients (Bunch et al., 2016).    
Overall, there is a lack of effective therapies for AF. This, in part, is due to an 
incomplete understanding of the complex pathophysiology of AF. The important 
outcome of genetic studies is that they can further elucidate the potential molecular 
mechanisms and find potential targets for therapy. Currently, AF response to treatment is 
highly variable among patients. This is thought to be partially due to slight differences in 
disease mechanisms between individuals. Some of these mechanisms include changes in 
the atrial action-potential duration, conduction slowing, weakened cell-to-cell 
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communication, modulation of signaling proteins, and atrial fibrosis and inflammation 
(Darbar & Roden, 2013).  
An SNP at the 4q25 locus (near PITX2) was shown to be significantly associated 
with successful symptom control with AAD. Also, these individuals who carried the 4q25 
SNP responded better to class I versus class III AADs (Parvez et al., 2012). The same 
group also found that the same locus near PITX2 was associated with AF reoccurrence 
after patients were treated by catheter ablation (Shoemaker et al., 2015). This further 
implicates that genetics can give us important information on how certain patients should 
be treated and how different subtypes of AF may exist. 
In this era of “personalized medicine” the field of pharmacogenetics is rapidly 
expanding. It is hoped that within the next five to ten years a more personalized approach 
will be taken to treat AF and that new drugs will be in development based on the targets 
identified in these genetic studies.   
VII. Current Study 
In the present study we sought to elucidate more of the far left of Figure 2. 
Namely, the rare variation that is highly penetrant. These are typically familial studies 
aimed at finding the causative mutation in families with hereditary patterns of disease 
(i.e. diseases with germline inheritance). The family that this study evaluates has a 
hereditary pattern of early-onset AF and atrial and ventricular septal defects (ASD and 
VSD respectively).  
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Figure 3. Phenotypic breakdown of family AF-772 (Ellinor, unpublished). 
 
Individual 7, the proband in the family, initially presented with shortness of 
breath, palpitations and two episodes of near syncope. Subsequent investigations revealed 
the presence of an ASD. She underwent surgery to correct an ostium primum ASD. Two 
of her descendants, 71 and 72, were diagnosed with AF at the ages of 14 and 16 years 
respectively. The proband´s sister, 2, had a single documented paroxysm of AF. The 
proband´s nephew, 22, had a VSD during childhood.  
The trait appears to be inherited in an autosomal dominant patteren with five 
members of the 16-member family having the disease. Three affected members of the 
family (22, 72, and 73) were exome sequenced and evaluated for genetic mutations. 
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Specific Aims and Objectives 
Because of the risks associated with AF and its widespread prevalence, effective 
treatment and prevention of the disorder is crucial. The study of the genetics involved can 
help expand our understanding of the molecular pathways to enable us to better clarify 
clinical implications and potential treatments for the disease. This study aims to identify 
and further elucidate the role of a genetic mutation found in a family with a hereditary AF 
and atrial and ventricular septal defects (ASD and VSD respectively). 
 
The specific aims of the study are: 
1. Identify the causative mutation in family AF-772 
2. Determine if variants in this gene could be present in other patients with early onset 
AF. 
3. Describe a functional assay characterizing two potential variants 
 
Different genetic polymorphisms associated with AF manifest themselves 
differently. This is important in assessing different therapeutic approaches, as different 
methods may be more effective in different patient populations depending on their 
genetics. Through this study we hope to develop a more comprehensive knowledge of the 
genetic causes for AF with the intention of contributing to different clinical interventions 
to help decrease the morbidity of this disease.  
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METHODS 
I. Clinical Evaluation of AF-772 
Sixteen members of the family underwent a standardized interview, physical 
examination, 12-lead electrocardiogram and echocardiography. Written informed consent 
was obtained from all patients prior to performing the evaluations. The study was 
approved by the Institutional Review Board at Massachusetts General Hospital (MGH) 
and complied with the Declaration of Helsinki. Affected individuals were identified as 
those with either AF on the electrocardiogram or patients with a documented ASD or 
VSD during echocardiographic analysis. 
 
II. Exome Sequencing of Family 
Previously our lab exome sequenced 3 members (22, 72, and 73) of a 16 member 
family (AF-772) with a complex phenotype of hereditary AF, ASDs, and a VSD (Figure 
3) using Agilent Sure Select Target Enrichment Assay (version 3) to isolate the exonic 
regions of their DNA and the Illumina HiSeq 2000 platform at Perkin Elmer (Waltham, 
MA, USA) for sequencing. 
Next, the short reads were aligned to a reference human genome (NCBI Build 37, 
hg19), in order to identify variants within the exons.  
III. Filtration and Prioritization 
Filtration and prioritization of the variants was performed according to previously 
published methods (Li, Gui, Kwan, Bao, & Sham, 2012). Synonymous variants and 
common variants (>0.01%, identified in publically available databases dbSNP, 1000 
Genomes Project (1000 Genomes Project Consortium et al., 2010), and Exome Variant 
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Server) were filtered out. Common variants are unlikely to be the disease causing 
mutation in instances of Mendelian disease because if a common variant was responsible 
for such a penetrant phenotype, one would see far more individuals in the general 
population with this disease. Additionally, variants that individuals 22, 72, and 73, did 
not have in common were also excluded from the analysis.  
The effect of the variants on protein coding was determined with Ref Gene from 
the University California, Santa Cruz (UCSC) (i.e. determining synonymous variants, or 
variants that do not change the amino acid). Prioritization of these variants was based on 
conservation of the amino acid among species using the Phylop tool, the predicted effect 
of the amino acid change on protein structure using the Poly-Phen-2 and SNAP tools, and 
their respective gene expression levels in the heart using the GNF Expression Atlas 2 data 
from U133A and GNF1H chips in UCSC browser. 
Sanger sequencing was used to confirm the presence of the variants and to 
perform segregation analysis for each individual of AF-772. Oligonucleotide primers 
flanking the putative variants were designed using cDNA and genomic sequences from 
the UCSC Genome Browser (hg19 assembly). Standard conditions were used to perform 
PCR. DNA sequencing was performed using the ABI PRISM dye terminator method 
(Applied Biosystems, CA, USA). 
IV. High Resolution Melting 
To determine if the GATA binding factor 6 (GATA6) variant found in AF-772 was 
present within the general population, we screened a cohort of patients from MGH with 
early onset AF using a combination of high resolution melting and Sanger sequencing. 
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Exons 3, 5 and 6 of the GATA6 gene were screened using high resolution melting 
whereas the remaining coding exons (2, 4 and 7) were sequenced directly using Sanger 
sequencing. Light Scanner technology (Idaho Technologies Inc. UT) was used to perform 
high resolution melting according to manufacturer’s recommendations. High resolution 
melting utilizes the fact that the melting temperature of DNA is entirely dependent on its 
sequence. Therefore, when screening a number of patient samples at once, variants in an 
individual’s sequence can be picked up by comparing their melt curves (using a 
fluorescent intercalating dye) to the other samples.  
V. Functional Assay of GATA6 
To determine the functional effects of the GATA6 variants our lab performed 
luciferase assays to measure wild-type GATA6 and our mutant construct’s transcriptional 
activity.  
The mammalian expression vector pCMV6 XL6 (Origene, MD, USA) was used 
for the luciferase assays. Site directed mutagenesis was used to introduce the P91S, 
A543G, and R585L variants into the wild type GATA6 construct (Quik Change kit, 
Stratagene, CA, USA). Primer sequences utilized for mutagenesis are included in Table 
1. Following introduction of the variant, the entire coding region was sequenced to ensure 
there were no additional variants. For the A177T variant, a 130 base pair oligonucleotide 
was synthesized by Genscript USA, which was then ligated into the double-restricted 
wild-type GATA6 construct.  
The functional effect of the variant was analyzed by performing luciferase assays 
using three luciferase reporter constructs, NPPA-promoter-luc, nautriuretuc peptide B 
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(NPPB)-promoter-luc, and the alpha subunit of myosin heavy chain (αMHC)-promoter-
luc. NPPA, NPPB and αMHC are downstream target genes for GATA transcription 
factors and harbor GATA dependent promoters (Charron, Paradis, Bronchain, Nemer, & 
Nemer, 1999). The NPPA, NPPB and αMHC promoter sequences (0.9 kb, 1.3 kb and 
0.7kb respectively) were amplified by a polymerase chain reaction (PCR) and subcloned 
into a pGL4.10 plasmid. Chinese hamster ovary (CHO) cells were transfected according 
to manufacturer specifications using Lipofectamine LTX (ThermoFisher, Waltham, MA, 
USA) with empty expression vector, wild-type GATA6 or mutant GATA6 expression 
vectors, and either the NPPA-promoter-luc, NPPB-promoter-luc, or αMHC-promoter-luc 
reporter constructs. 500ng of each construct was transfected into multiple replicates in a 
24-well plate. 100ng of the pRL-SV40 vector was also co-transfected in each group of 
cells as an internal transfection control.  
Additionally, the wildtype construct and each variant construct was also co-
transfected with either T-box transcription factor 5 (TBX5), GATA binding protein 4 
(GATA4), NK2 homeobox 5	  (NKX2.5) or Myocyte specific enhancer factor 2C (MEF2C) 
constructs and either the NPPA-promoter-luc, NPPB-promoter-luc, or αMHC-promoter-
luc reporter constructs. 
Firefly and Renilla luciferase activities were measured 24 hours post-transfection 
using the dual luciferase reporter assay system (Promega Corp, WI, USA). For statistical 
analyses, two-way ANOVA was performed followed by multiple comparisons with 
Bonferroni correction. A p-value of <0.05 was considered to be significant. 
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Table 1: Primers for Site-directed Mutagenesis 
 
Base substitutions are indicated in red. 
 
Confocal microscopy and Western blot analysis was also performed on wildtype CHO 
cells and CHO cells that had been transfected with each mutant construct.  
 
VI. Functional Assay of HHATL 
RNA was extracted from each cell line used and then reverse transcribed to 
cDNA using ProtoScript II First Strand cDNA Synthesis Kit (New England Biolabs, 
Ipswitch, MA, USA). Inherent expression of Hedgehog acyl transferase (HHAT), 
Hedgehog acyl transferase-like (HHATL), and glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) as a positive control was then determined using reverse 
transcription polymerase chain reaction (RT-PCR). Different sets of primers (Table 2) 
were designed for each cell line using Primer3Plus (Antergasser and Nijveen, 2007). For 
each primer pair the PCR settings were as follows, 95°C for 5 mins, then 95°C for 30 
seconds, 60°C for 1 minute, and 68°C for 1 minute (40 cycles), and finally 68°C for 5 
minutes.  
 
 
 Primer sequence 
R585L forward TCACGTCCTCCGTGCTACCGGATTCCTGGTGCGCC 
R585L reverse 
P91S forward 
P91S reverse 
A543G forward 
A543G reverse 
GGCGCACCAGGAATCCGGTAGCACGGAGGACGTGA 
CATCCCTTCGGGGCTTCCCACGGACCTTCG 
CGAAGGTCCGTGGGAAGCCCCGAAGGGATG 
AGGGGCGGGTGGCCCGGTGATGA 
TCATCACCGGGCCACCCGCCCCT 
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Table 2. Primers for RT-PCR  
HEK293_HHAT_F GCTGCCCCGATGGGAACTGG 
HEK293_HHAT_R AGGAGCTGAGACCGGAACTGGG 
HEK293_HHATL_F CGGGGCCTTGGCTGTGATGG 
HEK293_HHATL_F CTGCCTGGGCTCGGATGTGC 
HEK293_GAPDH_F TGGTCGTATTGGGCGCCTGG 
HEK293_GAPDH_R GCCAGGGGTGCTAAGCAGTTGG 
COS7_HHAT_F TGGACTCACTCCACCCGCCC 
COS7_HHAT_R GAGGGTCACCCAAGGCCAGC 
COS7_HHATL_F GCCTTCCGGGAGTCTGTGCG 
COS7_HHAT_R GTGGGCGCAGCTCTCCAGTG 
COS7_GAPDH_F TGGTCGTATTGGGCGCCTGG 
COS7_GAPDH_R GCCAGGGGTGCTAAGCAGTTGG 
CHO_HHAT_F TGCTGCCCCGATGGGAAATGG 
CHO_HHAT_R GCAGCCTCAGGGTGGAGAGC 
CHO_HHATL_F AAGTTTGCCAGCCGCCTCCC 
CHO_HHATL_R AGCCGGGCCTCGAATTGTGC 
CHO_GAPDH_F CGCCCCTTCTGCTGATGCCC 
CHO_GAPDH_R GTGGGCCCTCAGATGCCTGC 
 
The Sonic hedgehog (Shh) gene was received from plasmID at Harvard Medical 
School in a pENTR223.1 plamid. The HHAT and HHATL, and mutant HHATL constructs 
were synthesized by Gen 9 Bio (Cambridge, MA) in the pG9M plasmid. The original 
plamids were subjected to PCR to isolate the each desired gene. The Shh, HHATL and 
HHATL mutant constructs were subcloned into the pKH3 plasmid while the HHAT 
construct was subcloned into the pCDNA3 plasmid. The pKH3 plasmid was digested at 
the Xba and EcoRI sites and the pCDNA3 plasmid was digested at the XbaI and BamHI 
sites. Then, each gene was inserted into their respective plasmid by a Gibson reaction. 
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The HHATL and HHATL mutant constructs came with a FLAG-tag, however Shh and 
HHAT did not so the FLAG-tag was added manually using PCR primers (Table 3).  
 
Table 3. 
Primers for 
Flag Tagging  
 
Shh_Flag_F cttctgcaggtcgactgccaccATGCTGCTGCTGGCGAGA 
Shh Flag_R catggcggccatcgattgtcaGCTGGACTTGACCGCCATG 
HHAT_Flag_F caagcttggtaccgagctcgGCCACCATGCTGCCCCGA 
HHAT_Flag_R acactatagaatagggccctCTACTACTTGTCGTCATCGTCTTT
GTAGTCG 
 
Human embryonic kidney cells (HEK293), CHO and African green monkey 
kidney fibroblasts (COS7) cells were cultured according to recommendation. HEK293 
(6.25 X 105), COS7 (2.5X105), and CHO (2X105) cells were seeded onto a 6-well plate 
(35 mm/well) and transfected with each plasmid with Lipofectamine LTX and Plus 
reagent (ThermoFisher, Waltham, MA, USA).  
These cells were then lysed with lysis buffer containing 25 mM Tris-HCL, 5 mM 
EDTA, 5mM EGTA, 1% Triton X-100, 150 mM NaCl, 20 mM NaF, 0.2-1 mM Na3VO4, 
20 mM glycerol-2-phosphate, and protease inhibiter (Boston BioProducts, Ashland, MA, 
USA). The protein concentrations were then measured using a DC Protein Assay and 
iMark Microplate Reader (Bio-Rad, Hercules, CA, USA).  
10 µg of each sample was then subjected to sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) using 4-15% Mini-PROTEAN TGX polyacrylamide gels 
followed by a transfer to a polyvinylidene difluoride membrane using the Trans-Blot 
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Turbo Transfer System (Bio-Rad, Hercules, CA, USA). They were then blocked using 
5% skim milk in NaCl/Pi (PBS) containing 0.1% Tween. 
To determine the amount of modified 19-kDa Shh-Np the blots were probed with 
1:1000 H-160 and 5E1 antibodies along with anti-Flag, anti-GAPDH protein, and anti-
enhanced green fluorescent protein (EGFP) as internal controls. The blots were incubated 
overnight in an antibody/PBS/0.1%tween/5% dried milk solution. The blots were then 
washed in PBS/0.1% Tween 2 x 15 mins each. Next the blots were incubated with 
secondary antibodies at 1:10000 for 2 hours at room temperature. The blots were then 
washed again in PBS/0.1% tween 3 x 15 mins each and once with PBS for 5 minutes. 
The blots were analyzed using a Chemiluminescent Nucleic Acid Detection Module Kit 
(ThermoFisher Scientific, Waltham, MA) and ChemiDoc Touch Imaging System (Bio-
Rad, Hercules, CA, USA). 
The antibodies used were monoclonal anti-Shh N-terminal fragment (5E1, 1:1000; 
Developmental Studies Hybridoma Bank at the University of Iowa); rabbit anti-Shh N-
terminus (H-160, 1:1000; Santa Cruz Biotechnology Inc, Santa Cruz, CA); monoclonal 
anti-EGFP (JL-8, 1:1000; Fisher Scientific, Pittsburgh, PA); polyclonal anti-GAPDH 
protein conjugated with horseradish peroxidase (HRP) (FL-335,1:1000; Santa Cruz 
Biotechnology Inc, Santa Cruz, CA); HRP conjugated goat anti-mouse IgG (sc-
2031,1:10000, Santa Cruz Biotechnology Inc, Santa Cruz, CA); HRP-conjugated goat 
anti-rabbit IgG (ab6721-1, 1:10000; ABCAM, Cambridge, MA) 
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RESULTS 
The clinical data from family AF-772 (Figure 3) are summarized in Table 4. Five 
members of the family were affected and the trait appeared to be inherited in an 
autosomal dominant fashion. Individual 7, the proband, was diagnosed with an ostium 
primum ASD. Her children, 71 and 72 were diagnosed with AF at a young age, 14 and 16 
respectively. The probands sister, 2, had a single documented paroxysm of AF. The 
probands nephew, 22, had a VSD during childhood.   
 
Table 4. Clinical Characteristics of AF-772 Family Members 
 
 
AF, atrial fibrillation; HR, heart rate; LVEF, left ventricular ejection fraction; LA, left atrium; RV, right 
ventricular 
*Abnormal ECG with P wave inversion in lateral leads and right ventricular conduction delay 
 
From an analysis by our lab an average of 18,825 variants were found in individuals 22, 
72, and 73 via exome sequencing (Table 5). 
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Table 5: Number of Candidate Variants Identified by Exome Sequencing  
 
 
Filtering these variants to remove common, synonymous variants reported in 
population databases (dbSNP, 1000 Genomes, Exome Variant Server, and the EXac 
database) and variants that did not segregate with disease yielded a short list of 13 novel 
or very rare missense variants that individuals 22, 72, and 73 have in common (Table 6). 
Further prioritization was then based on gene expression profiles, interspecies 
conservation, predicted effect on protein function, and potential involvement with cardiac 
related functional pathways.  
Of these potentially interesting variants GATA6, Titin (TTN), HHATL, and 
Coiled-coil domain containing 69 (CCDC69) had high cardiac expression (i.e. protein 
present in cardiomyocytes). Ten variants were located on residues conserved throughout 
evolution (a Phylop score of greater than 0).   
 
 
 
 
Individual 22 72 73 
Total no. of variants 18,529 18,019 19,928 
No. of variants following filtration based on population 
databases  803 771 592 
No. of missense variants 548 521 385 
No. of nonsense variants 15 7 8 
No. of splice site variants 0 1 7 
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Table 6: List of Potentially Causative Genetic Variants in Family AF-772 
 
 
A more comprehensive segregation analysis was performed for five of the 13 
variants with high cardiac expression, a positive Phylop score, and had plausible links to 
cardiac disease after examination of the literature. Segregation analysis was performed by 
Sanger sequencing each region of interest in all 16 family members to determine whether 
or not they carried the variant. These results are included in Table 7.       
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Table 7: Segregation Analysis of Five Candidate Variants in Family AF-772 
 
 
Based on the segregation analysis and prioritization the R585L GATA6 was found 
to be the most compelling variant followed by HHATL as a close second (Tables 6 and 7 
and Figures 4 and 5).   
There were no significant differences between electrocardiogram (ECG) 
parameters (PR, QRS and QT intervals) between mutation carriers and patients without 
the mutation (GATA6-R585L genotype positive vs genotype negative; PR; 143±13 vs 
142±13 ms, p=0.85; QRS; 93±14 vs 84±12 ms, p=0.24; QT; 451±14 vs 430±19 ms, 
p=0.15). 
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Figure 4. GATA6 R585L variant segregation pattern in AF-772 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. HHATL K484N variant segregation pattern in AF-772 
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MGH AF Study 
Given our finding in AF-772 we screened a cohort of 546 patients with early 
onset AF. All patients in this cohort developed AF before the age of 66 and had 
structurally normal hearts. Table 8 includes a summary of the clinical characteristics of 
this cohort. We found three additional variants in the GATA6 gene in three separate 
individuals: A543G, P91S, and A177T.  
 
Table 8. Clinical Characteristics of Individuals with Early-Onset AF from the MGH 
AF Study 
 
 
 
 
 
 
 
 
 
 
 
 
 
Values are n (%) or mean ± SD. 
 
 
 
Study MGH AF Study 
Number 546 
Female 113 (20.7) 
Mean age, years 54.0 ± 10.5 
Mean age, onset 
AF 47.1 ± 10.9 
Family history of 
AF 246 (45.1) 
Hypertension 167 (30.6) 
Heart failure 18 (3.3) 
Diabetes 27 (4.9) 
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Table 9. Clinical Characteristics of Variant Carriers from the MGH AF Study 
 
 
 
 
 
 
 
 
 
Table 10. Location, frequency and conservation of GATA variant 
 
None of the patients had a family history of AF. Abbreviations: EF, ejection fraction; LA, left atrial; NA, 
Not available. 
 
 
 
 
 
 
 
 
    
 
 
 
Amino 
Acid 
Study  
Number Sex 
Age of  
onset 
(years) 
AF 
Pattern 
EF 
(%) 
LA 
Size 
(mm) 
 
QRS 
axis 
 
IVCD 
P91S 438 F 54 Permanent 63 NA 47 No 
A177 441 M 47 Paroxysmal 72 43 51 LBBB 
A543G 184 M 61 Paroxysmal 67 44 42 No 
Exon Nucleotide Amino Acid rs ID Phylop Polyphen GERP 
2 C271T P91S rs200620299 0.38 0.007 1.59 
2 G529A A177T - 1.34 0.991 2.36 
7 C1628G A543G - -0.13 0.010 -0.30 
7 G1754A R585L rs201707559 2.02 0.992 3.12 
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Figure 6. Summary of GATA6 variants found both in AF-772 and MGH cohort. 
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In order to determine these variants effects on protein function we performed a 
functional analysis of the variants found in GATA6. To do this we evaluated the ability of 
exogenously expressed wild-type and mutant GATA6 to activate known GATA family-
targeted promoters upstream of a luciferase reporter. We found that certain variants were 
concomitant with an upregulation in luciferase activity in NPPA (R585L: 4.1 fold, 
p<0.0001, P91S: 2.5 fold, p=0.0002, A117T:1.7 fold, p=0.03) and αMHC (R585L: 1.7 
fold, p=0.03, P91S; 1.7 fold, p=0.03) promoters (Figure 7). None of the variants showed 
any change in NPPB promoter activity. Also, the A543G mutant displayed no net effect 
in any of the constructs as compared to control.  
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Figure 7. A: Relative luciferase activity recorded from CHO cells following 
cotransfection of reporter constructs with GATA6, GATA4, TBX5, MEF2c, NKX2.5, or 
empty vector. B: Luciferase assay results for GATA6 wildtype and variants in NPPA, 
NPPB and αMHC promoters.  
In order to determine the mechanism of these functional effects we examined two 
common events that can cause changes in transcriptional activity: altered subcellular 
localization of the protein and differences in overall levels of the protein’s expression. 
However no difference was observed in subcellular localization or levels of protein 
expression as compared to the wildtype based on confocal microscopy and Western blot 
respectively (Figure 8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. A: Subcellular localization of GATA6 wildtype compared to GATA6 variants. B: 
Levels of protein expression in GATA6 wildtype versus GATA6 variants.  
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Wildtype GATA6 is found in the nucleus, the same results were found with 
overexpression of each of the variants in CHO cells. Similarly, Western blots of cellular 
lysate probed for GATA6 show that all of the constructs are expressing GATA6 at the 
same relative level.  
Because GATA6 is a transcription factor and transcription factors often do not 
work alone and come into contact with other transcription factors we sought to examine 
the effect of co-transfecting our GATA6 mutant constructs and other common 
transcription factors GATA6 is known to come in contact with. These transcription factors 
include: TBX5 (Maitra et al., 2009), GATA4 (Charron, Paradis, Bronchain, Nemer, & 
Nemer, 1999), NKX2.5 (Molkentin et al., 2000), and MEF2C (Morin, Charron, Robitaille, 
& Nemer, 2000).  
A difference in NPPA promoter activity was observed when GATA6 R585L and 
P91S variants were co-transfected with NKX2.5 or TBX5 and, more importantly, when all 
variants were co-transfected with GATA4 or MEF2C. A difference in NPPB promoter 
activity was observed only when R585L was co-transfected with either TBX5 or MEF2C. 
Finally a difference in αMHC promoter activity was observed when each GATA6 variant 
was co-transfected with TBX5, GATA4, or MEF2C (Figure 9.) When expressed 
independently of GATA6, TBX5, GATA4 and MEF2C had negligible effects of expression 
of the reporter constructs (Figure 7A).   
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Figure 9. Luciferase assays of GATA6 wildtype and variants co-transfected with either 
NKX2.5, TBX5, GATA4, or MEF2C with three different promotor constructs (NPPA, 
NPPB, and αMHC).  
A functional analysis of the HHATL variant was then performed based on 
previously described methods (Abe, Kita, & Niikura, 2008).  
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Figure 10. Inherent expression of HHAT, HHATL, and GAPDH in HEK293, COS7, and 
CHO cells. 
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Figure 11. Western blot of HHATL wildtype activity compared to HHATL variant activity 
in COS7 cells.  
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DISCUSSION 
By exome sequencing AF-772 and subsequently filtering and prioritizing the 
variants we were able to narrow down the disease causing mutation to two variants in two 
different genes, GATA6 and HHATL. We also found three additional variants in the 
GATA6 gene in a cohort of patients from MGH with early onset AF. Age is significant in 
this regard because mutations in younger patients with AF have greater genetic 
dependence with respect to their phenotypic expression (A Palatinus & Das, 2015). 
GATA6 is a known transcription factor and that contains a highly conserved DNA 
binding domain which consists of two zinc finger motifs that bind to the nucleotide 
sequence element (A/T)GATA(A/G) (Molkentin, 2000). Transcription factors help to 
initiate gene transcription and play a vital role in terms of gene expression. HHATL 
(hedgehog acyl transferase-like) inhibits HHAT (hedgehog acyl transferase), an important 
protein involved in the post-translational modification of Sonic Hedgehog (Shh), an 
important signaling protein involved in embryonic patterning and organogenesis. HHAT 
palmitoylates Sonic Hedgehog on its N-terminal Cys residue. This lipid modification 
affects Shh’s diffusibility, movement and concentration gradient and is therefore essential 
to Shh’s signaling capabilities during embryonic development (Abe, Kita, & Niikura, 
2008). Therefore, it is plausible that the mutant HHATL loses its ability to inhibit HHAT, 
which could in turn, affect Shh signaling during development and result in cardiac 
defects.  
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However, based on our functional assay results the HHATL mutant (did not cause 
any change in its functional activity. This would imply that the HHATL K484N is not 
responsible for AF-772 disease. However, further conformation of these results is needed. 
On the other hand, all four GATA6 variants we found exhibit gain-of-function 
modulation in luciferase assays (a measure of transcriptional activity) with up-regulation 
of NPPA and αMHC promoter activity. This could potentially be attributed to some sort 
of altered synergistic interaction between the variants and other transcription factors that 
GATA6 comes in contact with (Figure 9). For example, when all GATA6 variants were 
co-transfected with TBX5, GATA4, or MEF2C a difference in αMHC promoter activity 
was observed versus without co-transfection we only saw a difference αMHC promoter 
activity with R585L and P91S. This indicates that the presence of certain transcription 
factors can unmask a differential in some GATA6 variants’ activity that wouldn’t 
otherwise be detectable.  
Interestingly, these GATA6 variants were found in the N-terminus and C-terminus 
of the protein. This is noteworthy because these regions are thought to be important 
regulators of the protein’s function. If the variants were found in the zinc finger or 
transactivation domains they would likely cause detrimental effects that may not be 
compatible with life. Many previous studies further corroborate our findings that GATA6 
is the causative mutation in AF-772. GATA transcription factors have been found to play 
an important role in cardiac development and morphogenesis; mainly by activating the 
expression of terminal differentiation markers (Laverriere et al 1994). Additionally, 
GATA6 was found to have a key role in regulation differentiation of heart precursor cells; 
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when GATA6 levels were artificially elevated terminal differentiation in the heart is 
blocked (Gove, 1997). This is significant because it could lead to abnormal 
differentiation of cardiomyocytes which can contribute to triggering arrythmias (Zhang, 
Hartzell, Narlow, & Dudley, 2002).  
It has also been found that protein expression of GATA6 was dramatically 
increased in the adult mouse heart in response to pressure overload. The same study also 
examined the effect of a deletion of GATA6 in the adult heart and found a significant 
reduction in hypertrophic growth response, indicating a role in pathological cardiac 
hypertrophy (Berlo et al., 2010).  Another more recent study demonstrated similar results 
when they found that Sofroaphane decreased cardiac hypertrophy and also decreased 
levels of GATA6 protein (Kee, Kim, Kim, & Jeong, 2015). Another study showed GATA6 
gene expression in stem cell derived SA and AV nodal cardiomyocytes (Hashem & 
Claycomb, 2013). Importantly, these studies shows that, in addition to having an 
important role during development, GATA6 also regulates gene expression in the adult 
heart and it’s possible that the GATA6 gene plays some sort of role in maintaining the 
electrical conduction system in the adult heart.  
GATA6 variants have previously been implicated in cardiac abnormalities and 
congenital defects including atrioventricular septal defects and Tetrology of Fallot, and 
patent ductus arteriosus (Maitra, Koenig, Srivastava, & Garg, 2010) (Wang et al., 2012) 
(Kodo et al., 2009). Importantly, in addition to studies linking GATA6 mutations with 
structural cardiac defects, candidate-gene studies have identified four variants in the 
GATA6 gene in patients with AF. One study examined a cohort of 110 Chinese Han 
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patients with AF and found two novel variants (Q206P and Y265X), as compared to the 
control population (Yang et al., 2012). Another study the same group found an additional 
variants (Y235S) in a separate cohort. Similarly, Lin et al found another mutation in 
GATA6 (G469V) in patients with lone AF. The variants G469V and Y235S have been 
functionally validated, and in contrast to our findings, they resulted in a loss of GATA6 
function. 
Limitations 
Individuals 21, 3, and 9 carried the GATA6 variant but did not display any overt 
structural cardiac abnormalities or arrhythmias. Individual 3 did however demonstrate a 
very abnormal P wave axis with P wave inversion in the lateral leads (I and AVL) and 
evidence of right ventricular conduction delay. Individuals 9 and 21 had normal baseline 
ECGs. These findings may suggest that the GATA6-R585L variant is incompletely 
penetrant. However we cannot make this conclusion without further clinical evaluation. 
Perhaps these individuals may develop AF later on in life. Without more extensive 
clinical evaluation we were unable to exclude subtle septal defects and asymptomatic 
episodes of AF in these individuals. 
The complex phenotype of the family is also difficult to assess. Since congenital 
heart disease often leads to AF, could the mutation that was found in this family be 
causing congenital heart disease which in turn makes them more susceptible to AF? It’s 
possible that individuals 2, 72, and 73 had an undetected heart defect contributing to their 
AF. However, the more likely explanation is that different mutations can manifest 
themselves different in individuals depending on their genetic make-up. Previous studies 
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have also found that a specific mutation in a transcription factor can result in multiple 
different phenotypes (Seidman & Seidman, 2002). 
Additionally, the R585L identified in Family AF-772 and the P91S and A543G 
variants found in individuals with early-onset AF, were identified in rare individuals in 
the 1000 Genomes Project and the ExAC database, but not in the Exome Variant Server. 
This highlights the limitations of using SNP repository data as a “control” population in 
the absence of clinical data. It is possible that the individuals with these variants in the 
databases could have AF, and ASD, or VSD. However, the transmission of R585L in the 
family as well as the clear gain-of-function effect strongly support the role of this variant 
in the pathogenesis of the phenotype.  
Further studies 
As stated previously, it would be interesting to re-evaluate the family members 
more comprehensively and see if any of them (particularly individuals 21, 3, and 9) have 
developed AF or any other heart problems.  
Analyzing the phenotype of a cardiac specific mouse knock-out, knock-down, and 
overexpression of GATA6 would give us a better understanding of GATA6’s role in the 
heart. Additionally, electrophysiological studies on transgenic mice with the specific 
mutations we found in AF-772 and the MGH cohort would be a beneficial functional 
model of the variants. 
Another potential avenue could be to create knock-down and overexpression lines 
of GATA6 in cardiomyocytes to see if cardiomyocyte differentiation patterns are 
impacted or if there is any cellular phenotypic difference, such as prolonged APD.    
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